{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}],"title":"Hemoglobin Any Grade"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"title":"Hemoglobin Grade 3-4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}],"title":"Lymphocytes Any Grade"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}],"title":"Lymphocytes Grade 3-4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}],"title":"Neutrophils Any Grade"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"}]}],"title":"Neutrophils Grade 3-4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"}]}],"title":"Platelet Count Any Grade"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}],"title":"Platelet Count Grade 3-4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}],"title":"Leukocytes Any Grade"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}],"title":"Leukocytes Grade 3-4"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"description":"National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 3.0 was used to measure toxicity scale. Lower Limits of Normal (LLN). Hemoglobin Gr 1:\\<LLN to 10.0 g/dL, Gr 2:\\<10.0 to 8.0 g/dL, Gr 3:\\<8.0 to 6.5 g/dL, Gr 4:\\<6.5 g/dL. Lymphocytes (absolute) Gr 1: \\<1.5 to 0.8 \\*10\\^3 c/µL, Gr 2 \\<0.8 to 0.5 \\*10\\^3 c/µL, Gr 3: \\<0.5 to 0.2 \\*10\\^3 c/µL, Gr 4: \\<0.2\\*10\\^3 c/µL. Neutrophils (absolute): Gr 1:\\<LLN to 1.5\\*10\\^9/L, Gr 2:\\<1.5 to 1.0\\*10\\^9/L, Gr 3:\\<1.0 to 0.5\\*10\\^9/L, Gr 4:\\<0.5\\*10\\^9/L. Platelet count Gr 1:LLN to 75.0\\*10\\^9/L, Gr 2:\\<75.0 to 50.0\\*10\\^9/L, Gr 3:\\<50.0 to 25.0\\*10\\^9/L, Gr 4:\\<25.0 to 10\\^9/L. Leukocytes Gr 1:\\<LLN to 3.0 \\*10\\^3 c/µL, Gr 2; \\<3.0 to 2.0 \\*10\\^3 c/µL, Gr 3: \\<2.0 to 1.0 \\*10\\^3 c/µL, Gr 4: \\<1.0 \\*10\\^3 c/µL.","groups":[{"description":"Elotuzumab was administered IV at a dose of 10 mg/kg weekly (Days 1, 8, 15 and 22 of 4-week cycle) for the first 2 cycles and bi-weekly (every 2 weeks) (Day 1 and Day 15) thereafter until disease progression or unacceptable toxicity became apparent. Lenalidomide 25 mg was administered PO once daily for the first 3 weeks of each 4-week cycle. The dose of lenalidomide was administered at least 2-4 hours after completion of elotuzumab infusion. On weeks without elotuzumab administration, dexamethasone was administered PO as a single dose of 40 mg. On weeks of elotuzumab infusion, the weekly dose of dexamethasone was administered as a split dose of: 28 mg PO (between 3 to 24 hours prior to the start of the elotuzumab infusion) and 8 mg IV (At least 45 min prior to the start of the elotuzumab infusion).","id":"OG000","title":"Elotuzumab 10 mg/kg"},{"description":"Elotuzumab was administered IV at a dose of 20 mg/kg weekly (Days 1, 8, 15 and 22 of 4-week cycle) for the first 2 cycles and bi-weekly (every 2 weeks) (Day 1 and Day 15) thereafter until disease progression or unacceptable toxicity became apparent. Lenalidomide 25 mg was administered PO once daily for the first 3 weeks of each 4-week cycle. The dose of lenalidomide was administered at least 2-4 hours after completion of elotuzumab infusion. On weeks without elotuzumab administration, dexamethasone was administered PO as a single dose of 40 mg. On weeks of elotuzumab infusion, the weekly dose of dexamethasone was administered as a split dose of: 28 mg PO (between 3 to 24 hours prior to the start of the elotuzumab infusion) and 8 mg IV (At least 45 min prior to the start of the elotuzumab infusion).","id":"OG001","title":"Elotuzumab 20 mg/kg"}],"paramType":"NUMBER","populationDescription":"All participants who received at least one dose of study medication were summarized.","reportingStatus":"POSTED","timeFrame":"First dose (Day 1) to last dose plus 60 days (assessed up to January 2017, approximately 71 months)","title":"Number of Participants With Worst Toxicity Grade Hematology Laboratory Tests","type":"PRIMARY","unitOfMeasure":"participants"}